Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Controlled Trial of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women.

Next Previous
X
Search
Trial Profile

Randomized Controlled Trial of Teriparatide for the Treatment of Idiopathic Osteoporosis in Premenopausal Women.

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 24 Jan 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Teriparatide (Primary)
  • Indications Osteoporosis
  • Focus Therapeutic Use

    • Most Recent Events

    • 01 Jan 2023 Results of a preplanned analyses from parent and extension studies (NCT01440803 and NCT02049866) of high-resolution peripheral quantitative computed tomography scans assessing effects on volumetric BMD, microarchitecture, and estimated strength at distal radius and tibia published in the Journal of Bone and Mineral Research
    • 16 Apr 2022 Results from NCT01440803 and NCT02049866 , defining effects of treatment with teriparatide followed by denosumab on Lumbar Spine (LS) volumetric BMD (vBMD) and stiffness by finite element analysis assessed on central QCT scan, published in the Journal of Clinical Endocrinology and Metabolism
    • 01 Oct 2020 Results published in the Journal of Clinical Endocrinology and Metabolism

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top